Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
Stem Cell Therapeutics Corp. announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase.

In collaboration with a contract manufacturing organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process to generate drug for formal toxicology studies and a subsequent phase I clinical study, which is anticipated to begin in H2/2015.

SCT’s program targets the activity of CD47, a molecule upregulated on many leukemias and solid tumors. CD47 delivers a “do not eat” signal that suppresses macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to escape immunemediated destruction. SCT has chosen to block the CD47 protein using a modified version of its natural ligand, SIRPα, fused to an immunoglobulin Fc region. The SIRPαFc fusion protein has shown excellent anti-leukemic activity both in vitro and in human xenograft models, and exhibits a unique binding profile compared to other CD47 blocking agents. These results, as well as encouraging safety data emerging from a recently completed non-human primate study, will be reported at a future scientific conference.

“We believe that SIRPαFc, through its ability to activate the innate immune response and eliminate cancer stem cells, holds great promise as a novel immunotherapy,” commented Dr. Niclas Stiernholm. “The transition from the research to the IND-enabling phase is a key milestone for the SIRPαFc program, and we will continue on the path towards clinical testing”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stem Cell Therapeutics Corp: Traumatic Brain Injury Clinical Study Gains IRB Approval at University of Calgary
The study is a single center open label study to characterize the safety of hCG and EPO in traumatic brain injury patients.
Wednesday, August 18, 2010
Stem Cell Therapeutics Corp. Announces Top-Line Results for the Modified REGENESIS Phase IIb Stroke Trial
Results show substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those receiving NTx®-265.
Wednesday, May 26, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos